HOME | CONTACT US | FRANÇAIS

Newsroom 2006

November 16, 2006
Neurochem announces initial purchaser's exercise of over-allotment option for the purchase of senior convertible notes
November 9, 2006
Neurochem Announces Closing of Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible Notes with a Conversion Premium of 20%
November 8, 2006
Neurochem reports results for third quarter of fiscal 2006 Neurochem will host a conference call on Thursday, November 9, 2006, at 8:30 A.M. ET. LAVAL, QC, Nov. 8 /CNW/
November 7, 2006
Neurochem to Report on Third Quarter of Fiscal 2006 Neurochem will host a conference call Thursday, November 9, 2006, at 8:30 A.M. ET LAVAL, QC, Nov. 7 /CNW Telbec/ - Neurochem...
November 6, 2006
Neurochem receives recommendations from data safety monitoring boards to continue phase III clinical trials for tramiprosate (ALZHEMED(TM))
November 4, 2006
Neurochem Announces Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible Notes with a Conversion Premium of 20%
November 3, 2006
Neurochem to Present at Upcoming Healthcare Conferences
November 2, 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology Tramiprosate (ALZHEMED(TM)) Currently in Large Phase III Clinical Trials in North America and Europe
October 16, 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM) ECUBLENS, Switzerland, Oct. 16 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a wholly-owned...
September 28, 2006
Neurochem Marketing Authorization Application for Kiacta(TM) accepted for review by EMEA ECUBLENS, Switzerland, Sept. 28 /CNW Telbec/ - Neurochem (International) Limited (Neurochem), a...
September 21, 2006
Neurochem to present at UBS Global Life Sciences Conference LAVAL, QC, Sept. 21 /CNW Telbec/ - Neurochem Inc.
August 18, 2006
Neurochem announces resignation of a director LAVAL, QC, Aug. 18 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced today that Mr. Ronald Nordmann has resigned from the...
August 11, 2006
Neurochem receives approvable letter for eprodisate (Kiacta(TM)) for treatment of AA amyloidosis - Neurochem will host a conference call on August 14, 2006, at 8:30 A.M. ET LAVAL, QC, Aug....
August 9, 2006
Neurochem reports results for second quarter of fiscal 2006 - Announces Equity Line of Credit Facility
August 9, 2006
Neurochem to report on second quarter 2006 - Neurochem will host a conference call Wednesday, Aug. 9, 2006, at 5:00 P.M. ET
June 22, 2006
Eprodisate (Fibrillex(TM)) data presented at the meeting of the European League Against Rheumatism (EULAR)
June 12, 2006
Neurochem announces award denying majority of Immtech's claims
May 30, 2006
Tramiprosate (Alzhemed(TM)) preclinical results published in Neurobiology of Aging
May 24, 2006
NEUROCHEM and BMO support an expedition to Alaska for Alzheimer's disease - The ALASKA 2006 expedition will be undertaken by four young entrepreneurs from Montreal
May 24, 2006
/R E P E A T/ - Media invitation - NEUROCHEM and BMO support an expedition to Alaska for Alzheimer's disease
May 23, 2006
Media invitation - NEUROCHEM and BMO support an expedition to Alaska for Alzheimer's disease
May 9, 2006
Neurochem reports results for first quarter of fiscal 2006
May 9, 2006
At Annual General Meeting of Shareholders Neurochem highlights important developments for key product candidates - The Company Announces New Appointments
May 9, 2006
/R E P E A T/ - Invitation - Neurochem's Annual general Meeting of Shareholders May 9, 2006
May 8, 2006
Invitation - Neurochem's Annual general Meeting of Shareholders May 9, 2006
April 24, 2006
Neurochem presents an update on tramiprosate (Alzhemed(TM)) program for the treatment of Alzheimer's disease at 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
April 20, 2006
Neurochem to present at UBS Global Specialty Pharmaceuticals Conference and at 6th Annual Fortis Bank Biotechnology Conference
April 18, 2006
Neurochem announces eprodisate (Fibrillex(TM)) NDA filed and granted priority review by FDA for the treatment of AA amyloidosis
March 30, 2006
Neurochem to present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
February 23, 2006
Neurochem reports results for fourth quarter and fiscal year 2005
February 23, 2006
Neurochem to report on fourth quarter and fiscal year 2005
February 21, 2006
Neurochem receives fourth recommendation from Independent Safety Review Board for Alzhemed(TM)